Free Trial
NASDAQ:CYCN

Cyclerion Therapeutics 7/28/2023 Earnings Report

Cyclerion Therapeutics logo
$3.15 -0.10 (-2.95%)
Closing price 05/23/2025 03:55 PM Eastern
Extended Trading
$3.23 +0.08 (+2.44%)
As of 05/23/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cyclerion Therapeutics EPS Results

Actual EPS
-$1.83
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cyclerion Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cyclerion Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cyclerion Therapeutics' next earnings date is estimated for Tuesday, August 5, 2025, based on past reporting schedules.

Conference Call Resources

Cyclerion Therapeutics Earnings Headlines

Cyclerion Therapeutics files $25M mixed securities shelf
3 US Penny Stocks With Market Caps Over $10M To Consider
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Cyclerion Therapeutics announces update on next stage of growth
See More Cyclerion Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclerion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclerion Therapeutics and other key companies, straight to your email.

About Cyclerion Therapeutics

Cyclerion Therapeutics (NASDAQ:CYCN), a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

View Cyclerion Therapeutics Profile

More Earnings Resources from MarketBeat